2026-01-04 - Analysis Report
Okay, here's a comprehensive analysis of Schrodinger Inc. (SDGR) based on the data provided.

**Schrodinger Inc. (SDGR): A Computational Chemistry Company Focused on Drug Discovery and Materials Science.**

**1) Performance vs. S&P 500 (VOO):**

*   **Numbers:**
    *   SDGR Cumulative Return: -54.41%
    *   VOO Cumulative Return: +64.25%
    *   Divergence: -118.66%
    *   Relative Divergence: 2.2
*   **Analysis:** SDGR has significantly underperformed the S&P 500.  The divergence is extremely negative (-118.66%), indicating a considerable difference in returns. The relative divergence of 2.2 suggests that SDGR's current performance is near the lowest end of its historical range of divergence from the S&P 500.

**Alpha, Beta Analysis:**

*   **Data:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | -57.0% | 52.9% | -58.0% | 1.8 | 2.6 |
| 2022-2024  | 6.0% | 46.6% | -13.0% | 1.8 | 1.4 |
| 2023-2025  | -4.0% | 46.6% | -66.0% | 1.8 | 1.3 |

*   **Analysis:**
    *   **CAGR:** The Compound Annual Growth Rate (CAGR) shows mixed performance over the given periods, with significant negative returns in 2021-2023 and 2023-2025.
    *   **MDD:** The Maximum Drawdown (MDD) indicates substantial risk, with MDDs consistently above 46%, reflecting significant declines from peak to trough.
    *   **Alpha:** The negative Alpha values suggest that SDGR has underperformed relative to its benchmark (likely the S&P 500), even after accounting for market risk.
    *   **Beta:** The Beta values around 1.8 indicate that SDGR is more volatile than the market.
    *   **Cap(B):** Market capitalization has decreased from 2021-2023 to 2023-2025.

**2) Recent Stock Price Fluctuations:**

*   **Numbers:**
    *   Close: $17.98
    *   Previous Close: $17.88
    *   Change: +0.56%
    *   5-day SMA: $17.96
    *   20-day SMA: $18.03
    *   60-day SMA: $18.78
*   **Analysis:**  The stock price is currently slightly below both its 20-day and 60-day moving averages.  The 5-day SMA is very close to the current price, suggesting the price is hovering near its short-term average. The recent price change indicates a slight upward movement.

**3) Technical Indicators and Hybrid Signal:**

*   **Numbers:**
    *   MRI: 0.8 (Medium Investment)
    *   RSI: 48.56
    *   PPO: 0.13
    *   Recent Relative Divergence Change: +1.5 (Short-term increase)
    *   Expected Return: -2839.2%
*   **Analysis:**
    *   **MRI:**  The Market Risk Indicator suggests a medium investment recommendation based on its risk profile.
    *   **RSI:** The RSI is close to 50, suggesting neutral momentum.  It is neither overbought nor oversold.
    *   **PPO:** The Positive Price Oscillator (PPO) is slightly positive (0.13), suggesting a small bullish signal.
    *   **Recent Relative Divergence Change:** The positive change indicates a short-term increase in relative divergence, suggesting a short-term rise.
    *   **Hybrid Signal:** The Hybrid Signal indicates that you need to put 90% of cash into buy.
    *   **Expected Return:** The Expected Return is extremely negative (-2839.2%), indicating a very pessimistic outlook based on the model used to generate this figure. The expected excess return compared to the S&P 500 is also significantly negative.

**4) Recent News & Significant Events:**

*   **Summary of Headlines:**
    *   Analyst Upgrades: BofA upgraded SDGR to "Buy" citing a strategic pivot to software.
    *   Price Target Increases: New analyst forecasts have set price targets around $24.
    *   "Buy the Bottom" Potential:  Some sources suggest SDGR is a good "buy the bottom" stock.
    *   AI Drug Discovery Comparison:  SDGR is compared to RXRX in terms of upside potential.
*   **Analysis:** The news is mixed but leans somewhat positive.  The analyst upgrades and price target increases are bullish signals. However, the comparison with RXRX and "buy the bottom" suggestions imply some perceived risk or undervaluation.

**4-2) Analyst Opinions:**

*   **Numbers:**
    *   Mean Analyst Rating: Not Available
    *   Number of Opinions: 9
    *   Target Price:
        *   Average: $27.22
        *   High: $33.00
        *   Low: $18.00
*   **Analysis:** The average analyst target price of $27.22 suggests potential upside from the current price of $17.98.  However, the wide range between the high and low targets indicates uncertainty in the outlook. The lack of recent rating change details is a limitation.

**5) Recent Earnings Analysis:**

*   **Data:**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-11-05 | -0.45 | 0.05 B$  |
| 2025-08-06 | -0.59 | 0.05 B$  |
| 2025-05-07 | -0.82 | 0.06 B$  |
| 2024-11-12 | -0.52 | 0.04 B$  |
| 2025-11-05 | -0.52 | 0.04 B$  |

*   **Analysis:**
    *   **EPS:**  Earnings per share (EPS) have been consistently negative, indicating that the company is not currently profitable. EPS improved recently to -0.45 from -0.82.
    *   **Revenue:** Revenue has been relatively stable.

**6) Financial Information:**

*   **Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.05B  | 51.61%        |
| 2025-06-30 | $0.05B  | 47.77%        |
| 2025-03-31 | $0.06B  | 52.26%        |
| 2024-12-31 | $0.09B  | 72.61%        |
| 2024-09-30 | $0.04B  | 50.24%        |

*   **Capital and Profitability:**

| Quarter    | Equity | ROE      |
|------------|---------|----------|
| 2025-09-30 | $0.32B  | -10.21%  |
| 2025-06-30 | $0.34B  | -12.59%  |
| 2025-03-31 | $0.37B  | -16.01%  |
| 2024-12-31 | $0.42B  | -9.54%   |
| 2024-09-30 | $0.45B  | -8.49%   |

*   **Analysis:**
    *   **Revenue:** Revenue has fluctuated.
    *   **Profit Margin:**  Profit margins are relatively high, suggesting good cost control on the revenue being generated.
    *   **Equity:** Equity has been decreasing, suggesting the company is burning cash.
    *   **ROE:**  Return on Equity (ROE) is negative, reflecting the company's lack of profitability.

**7) Comprehensive Analysis (Summary):**

*   **Negative Performance:** SDGR has significantly underperformed the S&P 500 and exhibits high volatility (Beta).
*   **Unprofitable:**  The company is currently unprofitable, with negative EPS and ROE. Revenue and equity have declined.
*   **Mixed Signals:** While there are positive analyst upgrades and price target increases, the overall picture is mixed. Technical indicators suggest neutral momentum. The MRI indicates medium investment risk, while the "buy the bottom" sentiment suggests caution. The expected return is very negative.
*   **Strategic Pivot:**  The analyst upgrade hinges on the company's strategic pivot to software, implying a change in business direction that needs to be monitored.
*   **Financial Health Concerns:** Decreasing equity and negative ROE are concerning indicators of financial health.
*   **Investment Recommendation:** Based on this analysis, investing in SDGR appears **risky**.  The negative profitability, high volatility, and significant underperformance compared to the market are major concerns. The analyst upgrades and potential for a turnaround should be weighed against these risks. Further research is warranted before making an investment decision, particularly focusing on the success of the strategic pivot to software and the company's ability to achieve profitability.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.